Get the Stockscreener App
2.43
0.41%
0.01
After Hours:
2.41
-0.02
-0.82%
Fortress Biotech Inc stock is traded at $2.43, with a volume of 370.32K.
It is up +0.41% in the last 24 hours and down -21.61% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See More
Previous Close:
$2.42
Open:
$2.42
24h Volume:
370.32K
Relative Volume:
0.40
Market Cap:
$78.25M
Revenue:
$63.26M
Net Income/Loss:
$-32.92M
P/E Ratio:
-20.33
EPS:
-0.1195
Net Cash Flow:
$-71.34M
1W Performance:
+5.19%
1M Performance:
-21.61%
6M Performance:
-13.83%
1Y Performance:
+59.87%
1-Day Range:
$2.39
$2.49
1-Week Range:
$2.27
$2.49
52-Week Range:
$1.45
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.43 | 77.93M | 63.26M | -32.92M | -71.34M | -0.1195 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Aug Spikes: Is Fortress Biotech Inc part of any ETFPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Growth Value: How does Fortress Biotech Inc score in quality rankingsDay Trade & High Conviction Investment Ideas - baoquankhu1.vn
Sectors Review: Should value investors consider Fortress Biotech Inc2026 Performance Recap & Community Trade Idea Sharing Platform - baoquankhu1.vn
Liquidity Mapping Around (FBIOP) Price Events - Stock Traders Daily
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Maintains Target Price $4.5 - Moomoo
Institution Moves: Does Fortress Biotech Inc stock benefit from AI growth2026 Volume Leaders & Risk Controlled Daily Trade Plans - baoquankhu1.vn
FBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fortress Biotech Inc (FBIO) Stock Price, Trades & News - GuruFocus
FBIO PE Ratio & Valuation, Is FBIO Overvalued - Intellectia AI
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
FBIO SEC FilingsFortress Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS - MarketBeat
Fortress Biotech: Q4 Earnings Snapshot - Barchart.com
Fortress Biotech 2025 10-K: Revenue $63.3M, GAAP net loss $(32.9)M - TradingView
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) boosts cash with PRV sale, royalties - Stock Titan
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
Fortress Biotech Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView — Track All Markets
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Fortress Biotech Subsidiary Sells Rare Disease Priority Voucher for $205M - National Today
Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital - TipRanks
Fortress Biotech (NASDAQ: FBIO) targets $100M+ from Cyprium PRV sale - Stock Titan
Cyprium Therapeutics sells rare disease priority review voucher for $205 million - StreetInsider
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes - GlobeNewswire
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - Bitget
Why (FBIOP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aug Spikes: How do insiders feel about Fortress Biotech IncFed Meeting & Expert Curated Trade Ideas - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen - marketbeat.com
Fortress Biotech Inc Stock: Business Model, Pipeline Progress, and Investor Considerations in Biotec - AD HOC NEWS
Fortress Biotech Inc Stock: Journey Medical's Strong 2025 Results Highlight Growth Potential in Derm - AD HOC NEWS
Portfolio Recap: How does Fortress Biotech Inc score in quality rankingsOptions Play & Safe Entry Point Alerts - baoquankhu1.vn
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Portfolio Shifts: Can Fortress Biotech Inc deliver alphaQuarterly Earnings Summary & Smart Money Movement Alerts - baoquankhu1.vn
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday - MarketBeat
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Buyback Watch: How liquid is Fortress Biotech Inc stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Fortress Biotech (FBIO) CEO Lindsay Rosenwald reports 20.7% ownership in 13D/A - Stock Titan
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after the market closes on March 25. - 富途牛牛
Mustang Bio, Inc. 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, Risks, and Regulatory Overview - Minichart
Mustang Bio (NASDAQ: MBIO) details GBM pipeline, Orphan status and cash - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Understanding Momentum Shifts in (FBIOP) - Stock Traders Daily
Macro Review: How do insiders feel about Fortress Biotech IncMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewswire
Quarterly Earnings: Should value investors consider Fortress Biotech Inc2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Fortress Biotech Inc Stock (ISIN: US32015L1035) Faces Short Interest Pressure Amid Biotech Sector Vo - AD HOC NEWS
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):